A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study to investigate the safety and efficacy of the investigational drug,
zilovertamab, when given in combination with ibrutinib in patients with relapsed/refractory
(R/R) mantle cell lymphoma (MCL).